➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
McKinsey
AstraZeneca
Baxter
Johnson and Johnson

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LEVEMIR PENFILL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for LEVEMIR PENFILL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00810589 A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial Completed Medical University of Graz Phase 1 2008-11-01 Clinical pharmacology trials investigating insulin detemir in subjects with type 1 diabetes have shown a prolonged and reproducible action profile of insulin detemir compared with NPH insulin and insulin glargine. Duration of action of insulin detemir has been reported to be up to 24 hours.9,10,11 It has, however, been proposed that the mean duration of action is underestimated in glucose clamps lasting only 24 hours. This is so because a duration of action longer than 24 hours in individual clamps will be set to 24 hours in the mean calculation, whereas a shorter duration of action in individual clamps will be set to the true value. It has been shown in clinical pharmacology trials that NPL insulin has an action profile comparable to NPH insulin in subjects with type 1 diabetes. , However, a direct comparison of pharmacodynamic properties of insulin detemir and NPL insulin has not been performed to date. To get further insight into the pharmacodynamic properties of insulin detemir compared with NPL insulin, this trial has been designed to compare pharmacodynamics in general and duration of action in particular between insulin detemir and NPL insulin in subjects with type 1 diabetes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LEVEMIR PENFILL

Condition Name

Condition Name for LEVEMIR PENFILL
Intervention Trials
Diabetes, Type I 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LEVEMIR PENFILL
Intervention Trials
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LEVEMIR PENFILL

Trials by Country

Trials by Country for LEVEMIR PENFILL
Location Trials
Austria 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LEVEMIR PENFILL

Clinical Trial Phase

Clinical Trial Phase for LEVEMIR PENFILL
Clinical Trial Phase Trials
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LEVEMIR PENFILL
Clinical Trial Phase Trials
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LEVEMIR PENFILL

Sponsor Name

Sponsor Name for LEVEMIR PENFILL
Sponsor Trials
Medical University of Graz 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LEVEMIR PENFILL
Sponsor Trials
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Colorcon
Mallinckrodt
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.